Ravi Salgia

US Patent:

20100075320, Mar 25, 2010

Filed:

Feb 15, 2008

Appl. No.:

12/526870

Inventors:

Ravi Salgia - Park Ridge IL, US

International Classification:

C12Q 1/68
C07H 21/04

US Classification:

435 6, 536 231

Abstract:

Disclosed herein are methods for assessing risk of metastasis of a tumor in a mammal by determining the paxillin gene copy number per cell in the tumor or by detecting the presence of a paxillin mutation in the tumor. The presence of an increased paxillin gene copy number or a paxillin mutation is indicative of an increased risk of metastasis. Methods of staging tumors and methods of reducing invasiveness or metastasis of a cancer cell are also provided. Oligonucleotides comprising a paxillin mutation and antibodies capable of recognizing a paxillin mutant are disclosed.

US Patent:

20130217012, Aug 22, 2013

Filed:

Jun 3, 2011

Appl. No.:

13/701569

Inventors:

Ravi Salgia - Park Ridge IL, US
Soundarajan Krishnaswamy - Riyadh, SA
Yi-Hung Carol Tan - Chicago IL, US

International Classification:

C12Q 1/68
G01N 33/68

US Classification:

435 611, 435 79, 435 612, 435 71

Abstract:

The present invention relates generally to the fields of molecular biology and growth factor regulation. The invention concerns methods and compositions useful for diagnosing and treating human lung cancer associated with mutated c-CBL.

US Patent:

20060035907, Feb 16, 2006

Filed:

Feb 22, 2005

Appl. No.:

11/063033

Inventors:

James Christensen - San Diego CA, US
Ravi Salgia - Park Ridge IL, US

International Classification:

A61K 39/395
A61K 31/496
A61K 31/495
A61K 31/4745

US Classification:

514254090, 514291000, 424146100

Abstract:

The invention provides a method of treating abnormal cell growth in a mammal, such as a human, by administering to the mammal a therapeutically effective amount of a c-MET inhibitor and a mammalian target of rapamycin (mTOR) inhibitor.

US Patent:

20230065158, Mar 2, 2023

Filed:

Aug 23, 2022

Appl. No.:

17/893698

Inventors:

- Pasadena CA, US
Ravi SALGIA - Duarte CA, US

International Classification:

A61K 31/4995
A61K 39/395
A61K 31/7048
A61K 31/282
A61P 35/00
A61P 11/00

Abstract:

The present invention provides a method of treating a subject suffering from SCLC comprising administering to the subject an effective amount of a PP2A inhibitor and optionally one or more anti-cancer agents.

US Patent:

20210315911, Oct 14, 2021

Filed:

Apr 8, 2021

Appl. No.:

17/225970

Inventors:

- Duarte CA, US
Li Zheng - Duarte CA, US
Karen Reckamp - Duarte CA, US
Ravi Salgia - Duarte CA, US

International Classification:

A61K 31/665
A61K 31/517
A61K 31/5377
A61K 31/506
A61K 31/585
A61P 35/00

Abstract:

Provided herein, inter alia, are methods, compositions and kits for treating cancer in a subject. The methods include administration of one or more tyrosine kinase inhibitors and triptolide or an analog thereof to the subject. The methods, compositions and kits are effective for preventing resistance and/or increasing sensitivity to tyrosine kinase inhibitors.

US Patent:

20210139476, May 13, 2021

Filed:

Jun 21, 2018

Appl. No.:

16/623730

Inventors:

- Duarte CA, US
- Athens, GR
Ravi Salgia - Pasadena CA, US
Alexios-Leandros Skaltsounis - Athens, GR
Nikolaos Lougiakis - Athens, GR
Nicole Pouli - Athens, GR
Panagiotis Marakos - Athens, GR

International Classification:

C07D 471/04

Abstract:

Disclosed herein, inter alia, are pyridopyrazines and methods of using the same.

US Patent:

20200345693, Nov 5, 2020

Filed:

Aug 30, 2018

Appl. No.:

16/643051

Inventors:

- Duarte CA, US
- Athens, GR
Ravi Salgia - Pasadena CA, US
Alexios Leandros Skaltsounis - Athens, GR
Nicolas Gaboriaud-Kolar - Athens, GR
Panagiotis Gerolymatos - Athens, GR
Nikolaos Lougiakis - Athens, GR

International Classification:

A61K 31/4025
A61K 31/496
A61K 31/5377
C07D 409/04
C07D 409/14
C07D 413/14
A61K 45/06
A61P 35/00

Abstract:

Disclosed herein inter alia are compositions and methods for treating cancer using thioindirubin derivatives.